NCT01993212已完成3 期
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- Comparison of the proportion of subjects meeting the composite endpoint for normal morning testosterone and semen concentration.
研究概览
简要总结
This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with the 12.5 mg or 25 mg Androxal or AndroGel 1.62%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Overweight (BMI 25 to 42 kg/m2 inclusive) males age 18 to 60 inclusive
- •Previously or concurrently diagnosed as having secondary hypogonadism characterized as having at least 2 consecutive morning testosterone assessments < 300ng/dL, one of which must be confirmed at Baseline.
- •LH < 9.4 mIU/mL (at Visit 1 only)
- •Sperm concentration ≥ 15 million per milliliter (assessed at V2 and Baseline). V2 and Baseline measurements must be at least 48 hours apart.
- •Ability to complete the study in compliance with the protocol
- •Ability to understand and provide written informed consent
- •Agreement to provide a total of at least 4 semen samples in a sponsor-approved clinic on 4 separate occasions.
排除标准
- •Any prior use of testosterone treatments (injectable, pelleted, transdermal or sublingual) within the last 6 months
- •Use of spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study
- •Use of Clomid in the past year
- •Any clinically significant laboratory abnormality that does not have prior written sponsor approval. If the sponsor approves subject enrollment, this will not be considered to be a protocol deviation.
- •Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study, if considered clinically stable by the investigator. Newly diagnosed diabetics need to be treated for at least 48 hours before being enrolled in the study.
- •A hematocrit >54
- •Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
- •Known hypersensitivity to Clomid
- •Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2 based on 0-4 scale or any evidence of posterior subcapsular cataract)
- •Abnormal fundoscopy exam such as central retinal vein occlusion
- •Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study
- •Have received a diagnosis of irreversible infertility or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, vasectomy, or tumors of the pituitary), or history of evaluation or treatment for low fertility
- •Current or history of breast cancer
- •Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA>3.6
- •Presence or history of known hyperprolactinemia with or without a tumor (prolactin > 20 ng/mL).
- •Chronic use of medications such as glucocorticoids (chronic use of inhaled or topical glucocorticoids is acceptable)
- •History of drug abuse or chronic narcotic use including methadone
- •A recent history of alcoholism or illegal substance or steroid abuse (<2 years) or presence of moderate alcohol use (>21 drinks per week)
- •Subjects with known history of HIV and/or Hepatitis C
- •Subjects with end stage renal disease
- •History of liver disease (including malignancy) or a confirmed AST or ALT >3 times the upper limit of normal
- •History of clinically relevant myocardial infarction (within the previous year), unstable angina, symptomatic heart failure, ventricular dysrhythmia or know history of QTc interval prolongation
- •History of clinically relevant cerebrovascular disease
- •History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism)
- •History of erythrocytosis or polycythemia
- •Subjects unable to provide a semen sample in a sponsor-approved clinic
- •Enrollment in a previous Androxal study
- •Subjects who have Type I Diabetes
研究组 & 干预措施
Placebo
Placebo Comparator
Androxal Placebo and Gel Placebo
干预措施: Placebo Capsules (Drug)
Placebo
Placebo Comparator
Androxal Placebo and Gel Placebo
干预措施: Placebo Gel (Drug)
AndroGel Treatment
Active Comparator
AndroGel 1.62% and Placebo Capsules
干预措施: AndroGel 1.62% (Drug)
AndroGel Treatment
Active Comparator
AndroGel 1.62% and Placebo Capsules
干预措施: Placebo Capsules (Drug)
Androxal Treatment
Experimental
Androxal 12.5 mg or 25mg and Placebo Gel
干预措施: Androxal 12.5 mg or 25 mg (Drug)
Androxal Treatment
Experimental
Androxal 12.5 mg or 25mg and Placebo Gel
干预措施: Placebo Gel (Drug)
结局指标
主要结局
Comparison of the proportion of subjects meeting the composite endpoint for normal morning testosterone and semen concentration.
时间窗: 16 weeks of treatment
Comparison of the proportion of subjects whose morning testosterone levels are within the normal range \[300-1,040 ng/dL\] and whose sperm concentration is 15 million/mL or greater following 16 weeks of treatment with Androxal, placebo or AndroGel 1.62%.
次要结局
- Proportion of subjects with mean sperm concentration less than 15 million/mL after 16 weeks of treatment comparing Androxal to placebo in a non-inferiority assessment(16 weeks)
研究者
相似试验
已完成
3 期
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%Secondary HypogonadismNCT01993225Repros Therapeutics Inc.120
已完成
3 期
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLCStage II-III Non-small Cell Lung CancerNCT04158440Shanghai Junshi Bioscience Co., Ltd.501
已完成
3 期
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT06378697Akeso510
Unknown
3 期
Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical TrialChemotherapy-induced Peripheral NeuropathyColorectal CancerNCT04690283Nanjing NingQi Medicine Science and Technology Co., Ltd.360
招募中
3 期
A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT06383468Akeso420